DUGI KLAUS,GRAEFEMODY EVA ULRIKE,HARPER RUTH,WOERLE HANS-JUERGEN
申请号：
NZ62562109
公开号：
NZ625621A
申请日:
2009.08.05
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
The disclosure relates to the use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, which is a DPP-4 inhibitor, or a pharmaceutically acceptable salt thereof, for preparing a medicament for oral administration for treating and/or preventing of metabolic diseases in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin, wherein said DPP-4 inhibitor in the medicament is formulated for administration in an oral dose of 5 mg per day to said patients. Said medicament may be used in the treatment and/or prevention of type 2 diabetes mellitus in patients with at least one contraindication selected from: renal disease, renal impairment or renal dysfunction dehydration unstable or acute congestive heart failure acute or chromic metabolic acidosis and hereditary galactose intolerance. The disclosure also relates to the use of said DPP-4 inhibitor in combination with one or more further active substances selected from sulphonylureas, thiazolidinedones, glinides, alpha-glucosidase blockers, GLP-1 and GLP-1 analogues, and insulin and insulin analogues.
